Health Care • Biotechnology: Pharmaceutical Preparations
$58.08 ▲ +0.68
(+1.19%)
MKT CAP: $8.89B • VOL: 1.79M
52W L $27 52W H $62
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$49
MEDIAN
$65
MEAN
$66
HIGH
$79
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TGTX TAPE
TGTX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $70.28 | $66.79 | 2025-02-14 | $52.85 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $73.18 | $68.53 | 2025-02-06 | $54.60 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $66.21 | $63.89 | 2025-01-29 | $55.76 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $59.24 | — | 2025-01-17 | $56.92 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $51.11 | $55.18 | 2025-01-09 | $51.69 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $69.12 | $60.40 | 2024-12-18 | $50.53 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $56.34 | $58.66 | 2024-12-04 | $54.01 | -4.3% | 48% | C |